Clinical trials
Hepatitis B, Chronic trials in India
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 2 |
| 2022 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Active, not recruiting | 2 |
| Recruiting | 1 |
| Terminated | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bristol-Myers Squibb | 4 |
| Gilead Sciences | 4 |
| Novartis Pharmaceuticals | 4 |
| GlaxoSmithKline | 2 |
| Institute of Liver and Biliary Sciences, India | 2 |
| Composite Interceptive Med Science | 1 |
| Govind Ballabh Pant Hospital | 1 |
| Hoffmann-La Roche | 1 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hepatitis B, Chronic | 20 |
| Hepatitis B | 6 |
| Hepatitis | 4 |
| Hepatitis, Chronic | 3 |
| Bronchiolitis Obliterans Syndrome | 1 |
| DNA Virus Infections | 1 |
| Digestive System Diseases | 1 |
| Fibrosis | 1 |
| HIV Infections | 1 |
| Hepatitis, Viral, Human | 1 |
Trials
Showing 76 to 20 of 20. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.